Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
119-HRES-803119th CongressIntroduced Oct 10, 2025Health
Market Probability
No market
Status
Introduced
Committee
Floor Vote
Other Chamber
Signed
Referred to the House Committee on Energy and Commerce.
Sponsor
Rep. Rose, John W. [R-TN-6](R-TN-6)11 cosponsors
Actions (3)
Referred to the House Committee on Energy and Commerce.
Oct 10, 2025House floor actions
Submitted in House
Oct 10, 2025Library of Congress
Submitted in House
Oct 10, 2025Library of Congress